CN110082535B - Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof - Google Patents
Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof Download PDFInfo
- Publication number
- CN110082535B CN110082535B CN201910251994.7A CN201910251994A CN110082535B CN 110082535 B CN110082535 B CN 110082535B CN 201910251994 A CN201910251994 A CN 201910251994A CN 110082535 B CN110082535 B CN 110082535B
- Authority
- CN
- China
- Prior art keywords
- glu
- leu
- lys
- ala
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof. The invention finds that the occurrence of diseases caused by atherosclerosis such as chronic coronary heart disease can be predicted by detecting the concentration of MYH11 in a blood sample of a patient, and the method is used for diagnosing the chronic coronary heart disease.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to a molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof.
Background
Cardiovascular disease is one of the most important diseases currently threatening human health worldwide, and has become the first killer to endanger human health. Atherosclerosis (AS) is one of the leading causes of death from cardiovascular disease. According to recent statistics by the world health organization, about 1750 million patients who die globally annually from AS-related diseases account for 31% of the global mortality. The current situation in China is also worried, and according to the survey result of 'Chinese cardiovascular disease report 2017', 2400 million patients with AS-related diseases in 2017 have Coronary Heart Disease (CHD) which is one of the most main diseases, 1100 million patients have serious threats to the health of people. CHD is a heart disease caused by myocardial ischemia, hypoxia or necrosis due to stenosis or occlusion of blood vessels caused by atherosclerotic lesions occurring in coronary vessels. In the CHD disease, Chronic Coronary Heart Disease (CCHD) is characterized by long latent period, latent onset, short onset time, and light degree, which is generally caused by myocardial ischemia due to overwork, and the rest can be relieved. With the development of the disease, the disease gradually progresses to unstable angina, even myocardial infarction occurs. Moreover, patients with stable angina are at a higher risk of sudden death and are therefore severely life threatening. At present, the diagnosis of CCHD is mainly based on the disease symptoms of patients, which requires higher experience of doctors, so that the missed diagnosis is easy.
At present, the main means for diagnosing chronic cardiovascular diseases are imaging and electrocardiographic examination, including CT, MRI and electrocardiographic instruments. However, the methods of imaging and electrocardiographic examination usually require special instruments, the examination process is time-consuming, labor-consuming and expensive, and the results need to be interpreted by a very professional doctor, so that the methods are not suitable for large-scale screening and are not suitable for monitoring the course of disease and regular examination; and the sensitivity and specificity of diagnosis are not high, thus failing to meet the clinical requirements. The circulating biomarker detection has the advantages of economy, convenience, no wound, suitability for disease course monitoring, large-scale screening and the like, and has great application value. Therefore, research finding effective chronic cardiovascular disease-related markers should become a current focus of attention. At present, laboratory examinations on chronic cardiovascular diseases mainly comprise traditional biochemical markers such as triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, lipoprotein a, apolipoprotein A1, apolipoprotein B and the like. However, the diagnosis of stable angina pectoris by these markers has problems of low sensitivity and specificity. Many diseases unrelated to cardiovascular diseases cause the increase of the markers, thereby limiting the clinical application of the markers to a certain extent. Moreover, these markers are diagnostic for the onset of disease and cannot be used to prevent cardiovascular disease and reduce the incidence of chronic cardiovascular disease. Currently, about 1750 million deaths occur each year globally as a result of acute cardiovascular events, accounting for 31% of the global mortality. The Chinese situation is very severe, the number of people with coronary heart disease in 2017 is about 1100 thousands, and the death rate is increased year by year. However, the prior art lacks specific biomarkers for the diagnosis of chronic coronary heart disease.
Disclosure of Invention
In view of the above disadvantages of the prior art, the present invention aims to provide a molecular marker MYH11 for diagnosing chronic coronary heart disease and its application, which is used to solve the problem of lack of high specificity marker for diagnosing cardiovascular diseases such as chronic coronary heart disease in the prior art.
To achieve the above and other related objects, the present invention provides the use of a kit or diagnostic device for detecting the presence of a MYH11 protein for the preparation of a medicament for the diagnosis and/or prevention and/or treatment of chronic coronary heart disease, for in vitro diagnosis and/or risk stratification of chronic coronary heart disease.
Optionally, the kit is used for determining the expression amount of MYH11 protein in a body fluid sample.
Alternatively, the kit detects the expression amount of MYH11 protein by an ELISA method.
Optionally, the expression level of MYH11 protein in the body fluid sample is positively correlated with the severity of chronic coronary heart disease.
Optionally, the body fluid sample is selected from serum.
Optionally, the medicament is for diagnosing or monitoring the presence and/or the course and/or the severity and/or the prognosis of chronic coronary heart disease.
The invention also provides an application of the MYH11 protein or the peptide fragment thereof as a biomarker in diagnosis of chronic coronary heart disease, and the serum MYH11 is used for in vitro diagnosis and/or risk stratification of chronic coronary heart disease.
Chronic coronary heart disease is often caused by atherosclerosis.
Alternatively, MYH11 protein levels are highly expressed in patients with chronic coronary heart disease.
Alternatively, MYH11 protein ≧ 1990.0218pg/ml in the patient's serum can be diagnosed as chronic coronary heart disease.
The invention also provides application of the DNA for expressing the MYH11 protein or the mRNA or the functional homolog thereof as a biomarker in preparation or screening of diagnostic reagents for chronic coronary heart disease.
As mentioned above, the molecular marker MYH11 for diagnosing chronic coronary heart disease and the application thereof have the following beneficial effects: the invention finds that chronic coronary heart disease can be diagnosed by detecting the concentration of MYH11 in a serum sample of a patient with chronic coronary heart disease.
Detailed Description
The following embodiments of the present invention are provided by way of specific examples, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure herein. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
The novel diagnosis marker of the chronic cardiovascular disease is searched, and the novel diagnosis marker plays an important role in early diagnosis, early intervention, disease progression delay and reduction of morbidity, mortality and complications of the acute cardiovascular disease.
MYH11 is an important component of the MYH family, the MYH11 Gene encodes the myosin heavy chain of vascular smooth muscle cells, the amino acid sequence of the myosin heavy chain is shown in sequence 1, the genebank number of the nucleotide sequence is Gene ID:4629, the myosin heavy chain is an important component of a smooth muscle contraction unit, the myosin heavy chain is located in 16P13.11 of a human chromosome, and the myosin heavy chain comprises 40 exons and 39 introns. Mutation of MYH11 gene is closely related to vascular diseases. The study found that MYH11 gene mutation can cause aortic aneurysm occurrence, and most patients have incorporated incomplete arterial vessel occlusion. Mutation of the MYH11 gene results in changes in its structure, affecting the contractile function of smooth muscle cells, and resulting in decreased aortic compliance and elasticity and decreased vascular smooth muscle proliferation. This may be the cause of the aneurysm. However, the occurrence of MYH11 and chronic coronary heart disease is not yet clear. The role of MYH11 in CCH and its use as a diagnostic marker is also a hotspot in the field of cardiovascular research. At present, serum MYH11 is not used as a biomarker for diagnosing chronic coronary heart disease in the field, so that the development of a specific biomarker for stabilizing the diagnosis of angina is urgently needed.
The inventor has conducted extensive and intensive studies to detect the concentration of MYH11 in the serum of healthy people, HF (Heart Failure), ACS (Acute Coronary Syndrome) and CCHD (Chronic Coronary Heart Disease) patients by ELISA method, and found for the first time that the concentration of MYH11 in the serum of CCHD patients is significantly higher than that of healthy people (i.e. control group) and has no significant difference with the serum concentrations of HF patients and ACS patients. Thus, MYH11 may play a very important role in the development of CCHC, possibly as a potential biomarker for diagnosis and prediction of CCHC.
The serum samples used in the present invention were all derived from peripheral venous blood, with consent from volunteers. The peripheral venous blood samples including 18 healthy people, 9 heart failure patients, 23 ACS patients and 39 CCHD patients were collected; ELISA kits for detecting the concentration of MYH11 in serum were purchased from Biorbyt under the product name Human MYH11ELISA Kit, cat # orb404884, according to the instructions. The detection kit for the clinical biochemical marker indexes is purchased from Shenzhen Merrill biomedical electronics Limited, and is carried out according to an operation instruction, and comprises a Total Cholesterol (TC) determination kit (oxidase method), a product number: 105-; triglyceride (TG) assay kit (oxidase method), cat #: 105-001396-00; high density lipoprotein cholesterol (HDL-C) assay kit (direct method), cat #: 105-; low-density lipoprotein cholesterol (LDL-C) determination kit (direct method), cat 105 and cat 001411-00; apolipoprotein a1(ApoA1) assay kit (immunotransmission turbidimetry), cat No.: 105-; apolipoprotein b (apob) assay kit (immunotransmission turbidimetry), cat No.: 105-; lipoprotein (a) [ lp (a) ] assay kit (immunotransmission turbidimetry), cat No.: 105-; creatine Kinase (CK) assay kit (IFCC method), cat #: 105-; lactate Dehydrogenase (LDH) assay kit (IFCC method), cat #: 105-; homocysteine (HCY) assay kit (enzyme cycling method) cat number: 105-; myoglobin (MYO) assay kit (latex enhanced immuno transmission turbidimetry), cat #: 105-002798-00; c-reactive protein (CRP) assay kit (immunotransmission turbidimetry), cat No.: 105-; creatine kinase MB-type isozyme (CK-MB) assay kit (immunosuppressive method), cat #: 105-001406-00.
TABLE 1 expression levels of MYH11 in human serum samples
Table 1 Expression levels of MYH11 in human serum samples
Table 1 shows a statistical map of the expression levels of MYH11 in human serum samples, including the concentration of MYH11 in serum of healthy, CCHD, HF and ACS patients. Specifically, peripheral venous blood of a subject was extracted, and after serum was separated, concentrations of MYH11 in various sera were measured by ELISA. The serum concentration of MYH11 in CCHD group is significantly higher than that in healthy control group, while the serum concentration of patients with acute coronary syndrome of heart failure (HF group) is significantly different from that in healthy control group.
TABLE 2 correlation of MYH11 expression in human serum with clinical biochemical markers
Table 2 Correlation between MYH11 expression and clinical biochemical indexes in human serum
In table 2, the r value is a correlation coefficient in statistics. When the p value is less than 0.05, the larger the | r | value is, the better the correlation is, positive numbers refer to positive correlation, and negative numbers refer to negative correlation.
Table 2 shows the correlation of serum MYH11 concentration with clinical biochemical markers in the CCHD group of table 1. The serum MYH11 concentration of the CCHD group is in significant positive correlation with TG and ApoB concentration, and is in significant negative correlation with HDL. The concentration of serum MYH11 has no correlation with other clinical biochemical markers.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which may be made by those skilled in the art without departing from the spirit and scope of the present invention as defined in the appended claims.
SEQUENCE LISTING
<110> southern hospital of southern medical university
<120> molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof
<130> PCQNF192604
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1945
<212> PRT
<213> Artificial
<220>
<223> MYH11 amino acid sequence
<400> 1
Met Ala Gln Lys Gly Gln Leu Ser Asp Asp Glu Lys Phe Leu Phe Val
1 5 10 15
Asp Lys Asn Phe Ile Asn Ser Pro Val Ala Gln Ala Asp Trp Ala Ala
20 25 30
Lys Arg Leu Val Trp Val Pro Ser Glu Lys Gln Gly Phe Glu Ala Ala
35 40 45
Ser Ile Lys Glu Glu Lys Gly Asp Glu Val Val Val Glu Leu Val Glu
50 55 60
Asn Gly Lys Lys Val Thr Val Gly Lys Asp Asp Ile Gln Lys Met Asn
65 70 75 80
Pro Pro Lys Phe Ser Lys Val Glu Asp Met Ala Glu Leu Thr Cys Leu
85 90 95
Asn Glu Ala Ser Val Leu His Asn Leu Arg Glu Arg Tyr Phe Ser Gly
100 105 110
Leu Ile Tyr Thr Tyr Ser Gly Leu Phe Cys Val Val Val Asn Pro Tyr
115 120 125
Lys His Leu Pro Ile Tyr Ser Glu Lys Ile Val Asp Met Tyr Lys Gly
130 135 140
Lys Lys Arg His Glu Met Pro Pro His Ile Tyr Ala Ile Ala Asp Thr
145 150 155 160
Ala Tyr Arg Ser Met Leu Gln Asp Arg Glu Asp Gln Ser Ile Leu Cys
165 170 175
Thr Gly Glu Ser Gly Ala Gly Lys Thr Glu Asn Thr Lys Lys Val Ile
180 185 190
Gln Tyr Leu Ala Val Val Ala Ser Ser His Lys Gly Lys Lys Asp Thr
195 200 205
Ser Ile Thr Gln Gly Pro Ser Phe Ala Tyr Gly Glu Leu Glu Lys Gln
210 215 220
Leu Leu Gln Ala Asn Pro Ile Leu Glu Ala Phe Gly Asn Ala Lys Thr
225 230 235 240
Val Lys Asn Asp Asn Ser Ser Arg Phe Gly Lys Phe Ile Arg Ile Asn
245 250 255
Phe Asp Val Thr Gly Tyr Ile Val Gly Ala Asn Ile Glu Thr Tyr Leu
260 265 270
Leu Glu Lys Ser Arg Ala Ile Arg Gln Ala Arg Asp Glu Arg Thr Phe
275 280 285
His Ile Phe Tyr Tyr Met Ile Ala Gly Ala Lys Glu Lys Met Arg Ser
290 295 300
Asp Leu Leu Leu Glu Gly Phe Asn Asn Tyr Thr Phe Leu Ser Asn Gly
305 310 315 320
Phe Val Pro Ile Pro Ala Ala Gln Asp Asp Glu Met Phe Gln Glu Thr
325 330 335
Val Glu Ala Met Ala Ile Met Gly Phe Ser Glu Glu Glu Gln Leu Ser
340 345 350
Ile Leu Lys Val Val Ser Ser Val Leu Gln Leu Gly Asn Ile Val Phe
355 360 365
Lys Lys Glu Arg Asn Thr Asp Gln Ala Ser Met Pro Asp Asn Thr Ala
370 375 380
Ala Gln Lys Val Cys His Leu Met Gly Ile Asn Val Thr Asp Phe Thr
385 390 395 400
Arg Ser Ile Leu Thr Pro Arg Ile Lys Val Gly Arg Asp Val Val Gln
405 410 415
Lys Ala Gln Thr Lys Glu Gln Ala Asp Phe Ala Val Glu Ala Leu Ala
420 425 430
Lys Ala Thr Tyr Glu Arg Leu Phe Arg Trp Ile Leu Thr Arg Val Asn
435 440 445
Lys Ala Leu Asp Lys Thr His Arg Gln Gly Ala Ser Phe Leu Gly Ile
450 455 460
Leu Asp Ile Ala Gly Phe Glu Ile Phe Glu Val Asn Ser Phe Glu Gln
465 470 475 480
Leu Cys Ile Asn Tyr Thr Asn Glu Lys Leu Gln Gln Leu Phe Asn His
485 490 495
Thr Met Phe Ile Leu Glu Gln Glu Glu Tyr Gln Arg Glu Gly Ile Glu
500 505 510
Trp Asn Phe Ile Asp Phe Gly Leu Asp Leu Gln Pro Cys Ile Glu Leu
515 520 525
Ile Glu Arg Pro Asn Asn Pro Pro Gly Val Leu Ala Leu Leu Asp Glu
530 535 540
Glu Cys Trp Phe Pro Lys Ala Thr Asp Lys Ser Phe Val Glu Lys Leu
545 550 555 560
Cys Thr Glu Gln Gly Ser His Pro Lys Phe Gln Lys Pro Lys Gln Leu
565 570 575
Lys Asp Lys Thr Glu Phe Ser Ile Ile His Tyr Ala Gly Lys Val Asp
580 585 590
Tyr Asn Ala Ser Ala Trp Leu Thr Lys Asn Met Asp Pro Leu Asn Asp
595 600 605
Asn Val Thr Ser Leu Leu Asn Ala Ser Ser Asp Lys Phe Val Ala Asp
610 615 620
Leu Trp Lys Asp Val Asp Arg Ile Val Gly Leu Asp Gln Met Ala Lys
625 630 635 640
Met Thr Glu Ser Ser Leu Pro Ser Ala Ser Lys Thr Lys Lys Gly Met
645 650 655
Phe Arg Thr Val Gly Gln Leu Tyr Lys Glu Gln Leu Gly Lys Leu Met
660 665 670
Thr Thr Leu Arg Asn Thr Thr Pro Asn Phe Val Arg Cys Ile Ile Pro
675 680 685
Asn His Glu Lys Arg Ser Gly Lys Leu Asp Ala Phe Leu Val Leu Glu
690 695 700
Gln Leu Arg Cys Asn Gly Val Leu Glu Gly Ile Arg Ile Cys Arg Gln
705 710 715 720
Gly Phe Pro Asn Arg Ile Val Phe Gln Glu Phe Arg Gln Arg Tyr Glu
725 730 735
Ile Leu Ala Ala Asn Ala Ile Pro Lys Gly Phe Met Asp Gly Lys Gln
740 745 750
Ala Cys Ile Leu Met Ile Lys Ala Leu Glu Leu Asp Pro Asn Leu Tyr
755 760 765
Arg Ile Gly Gln Ser Lys Ile Phe Phe Arg Thr Gly Val Leu Ala His
770 775 780
Leu Glu Glu Glu Arg Asp Leu Lys Ile Thr Asp Val Ile Met Ala Phe
785 790 795 800
Gln Ala Met Cys Arg Gly Tyr Leu Ala Arg Lys Ala Phe Ala Lys Arg
805 810 815
Gln Gln Gln Leu Thr Ala Met Lys Val Ile Gln Arg Asn Cys Ala Ala
820 825 830
Tyr Leu Lys Leu Arg Asn Trp Gln Trp Trp Arg Leu Phe Thr Lys Val
835 840 845
Lys Pro Leu Leu Gln Val Thr Arg Gln Glu Glu Glu Met Gln Ala Lys
850 855 860
Glu Asp Glu Leu Gln Lys Thr Lys Glu Arg Gln Gln Lys Ala Glu Asn
865 870 875 880
Glu Leu Lys Glu Leu Glu Gln Lys His Ser Gln Leu Thr Glu Glu Lys
885 890 895
Asn Leu Leu Gln Glu Gln Leu Gln Ala Glu Thr Glu Leu Tyr Ala Glu
900 905 910
Ala Glu Glu Met Arg Val Arg Leu Ala Ala Lys Lys Gln Glu Leu Glu
915 920 925
Glu Ile Leu His Glu Met Glu Ala Arg Leu Glu Glu Glu Glu Asp Arg
930 935 940
Gly Gln Gln Leu Gln Ala Glu Arg Lys Lys Met Ala Gln Gln Met Leu
945 950 955 960
Asp Leu Glu Glu Gln Leu Glu Glu Glu Glu Ala Ala Arg Gln Lys Leu
965 970 975
Gln Leu Glu Lys Val Thr Ala Glu Ala Lys Ile Lys Lys Leu Glu Asp
980 985 990
Glu Ile Leu Val Met Asp Asp Gln Asn Asn Lys Leu Ser Lys Glu Arg
995 1000 1005
Lys Leu Leu Glu Glu Arg Ile Ser Asp Leu Thr Thr Asn Leu Ala
1010 1015 1020
Glu Glu Glu Glu Lys Ala Lys Asn Leu Thr Lys Leu Lys Asn Lys
1025 1030 1035
His Glu Ser Met Ile Ser Glu Leu Glu Val Arg Leu Lys Lys Glu
1040 1045 1050
Glu Lys Ser Arg Gln Glu Leu Glu Lys Leu Lys Arg Lys Leu Glu
1055 1060 1065
Gly Asp Ala Ser Asp Phe His Glu Gln Ile Ala Asp Leu Gln Ala
1070 1075 1080
Gln Ile Ala Glu Leu Lys Met Gln Leu Ala Lys Lys Glu Glu Glu
1085 1090 1095
Leu Gln Ala Ala Leu Ala Arg Leu Asp Asp Glu Ile Ala Gln Lys
1100 1105 1110
Asn Asn Ala Leu Lys Lys Ile Arg Glu Leu Glu Gly His Ile Ser
1115 1120 1125
Asp Leu Gln Glu Asp Leu Asp Ser Glu Arg Ala Ala Arg Asn Lys
1130 1135 1140
Ala Glu Lys Gln Lys Arg Asp Leu Gly Glu Glu Leu Glu Ala Leu
1145 1150 1155
Lys Thr Glu Leu Glu Asp Thr Leu Asp Ser Thr Ala Thr Gln Gln
1160 1165 1170
Glu Leu Arg Ala Lys Arg Glu Gln Glu Val Thr Val Leu Lys Lys
1175 1180 1185
Ala Leu Asp Glu Glu Thr Arg Ser His Glu Ala Gln Val Gln Glu
1190 1195 1200
Met Arg Gln Lys His Ala Gln Ala Val Glu Glu Leu Thr Glu Gln
1205 1210 1215
Leu Glu Gln Phe Lys Arg Ala Lys Ala Asn Leu Asp Lys Asn Lys
1220 1225 1230
Gln Thr Leu Glu Lys Glu Asn Ala Asp Leu Ala Gly Glu Leu Arg
1235 1240 1245
Val Leu Gly Gln Ala Lys Gln Glu Val Glu His Lys Lys Lys Lys
1250 1255 1260
Leu Glu Ala Gln Val Gln Glu Leu Gln Ser Lys Cys Ser Asp Gly
1265 1270 1275
Glu Arg Ala Arg Ala Glu Leu Asn Asp Lys Val His Lys Leu Gln
1280 1285 1290
Asn Glu Val Glu Ser Val Thr Gly Met Leu Asn Glu Ala Glu Gly
1295 1300 1305
Lys Ala Ile Lys Leu Ala Lys Asp Val Ala Ser Leu Ser Ser Gln
1310 1315 1320
Leu Gln Asp Thr Gln Glu Leu Leu Gln Glu Glu Thr Arg Gln Lys
1325 1330 1335
Leu Asn Val Ser Thr Lys Leu Arg Gln Leu Glu Glu Glu Arg Asn
1340 1345 1350
Ser Leu Gln Asp Gln Leu Asp Glu Glu Met Glu Ala Lys Gln Asn
1355 1360 1365
Leu Glu Arg His Ile Ser Thr Leu Asn Ile Gln Leu Ser Asp Ser
1370 1375 1380
Lys Lys Lys Leu Gln Asp Phe Ala Ser Thr Val Glu Ala Leu Glu
1385 1390 1395
Glu Gly Lys Lys Arg Phe Gln Lys Glu Ile Glu Asn Leu Thr Gln
1400 1405 1410
Gln Tyr Glu Glu Lys Ala Ala Ala Tyr Asp Lys Leu Glu Lys Thr
1415 1420 1425
Lys Asn Arg Leu Gln Gln Glu Leu Asp Asp Leu Val Val Asp Leu
1430 1435 1440
Asp Asn Gln Arg Gln Leu Val Ser Asn Leu Glu Lys Lys Gln Arg
1445 1450 1455
Lys Phe Asp Gln Leu Leu Ala Glu Glu Lys Asn Ile Ser Ser Lys
1460 1465 1470
Tyr Ala Asp Glu Arg Asp Arg Ala Glu Ala Glu Ala Arg Glu Lys
1475 1480 1485
Glu Thr Lys Ala Leu Ser Leu Ala Arg Ala Leu Glu Glu Ala Leu
1490 1495 1500
Glu Ala Lys Glu Glu Leu Glu Arg Thr Asn Lys Met Leu Lys Ala
1505 1510 1515
Glu Met Glu Asp Leu Val Ser Ser Lys Asp Asp Val Gly Lys Asn
1520 1525 1530
Val His Glu Leu Glu Lys Ser Lys Arg Ala Leu Glu Thr Gln Met
1535 1540 1545
Glu Glu Met Lys Thr Gln Leu Glu Glu Leu Glu Asp Glu Leu Gln
1550 1555 1560
Ala Thr Glu Asp Ala Lys Leu Arg Leu Glu Val Asn Met Gln Ala
1565 1570 1575
Leu Lys Gly Gln Phe Glu Arg Asp Leu Gln Ala Arg Asp Glu Gln
1580 1585 1590
Asn Glu Glu Lys Arg Arg Gln Leu Gln Arg Gln Leu His Glu Tyr
1595 1600 1605
Glu Thr Glu Leu Glu Asp Glu Arg Lys Gln Arg Ala Leu Ala Ala
1610 1615 1620
Ala Ala Lys Lys Lys Leu Glu Gly Asp Leu Lys Asp Leu Glu Leu
1625 1630 1635
Gln Ala Asp Ser Ala Ile Lys Gly Arg Glu Glu Ala Ile Lys Gln
1640 1645 1650
Leu Arg Lys Leu Gln Ala Gln Met Lys Asp Phe Gln Arg Glu Leu
1655 1660 1665
Glu Asp Ala Arg Ala Ser Arg Asp Glu Ile Phe Ala Thr Ala Lys
1670 1675 1680
Glu Asn Glu Lys Lys Ala Lys Ser Leu Glu Ala Asp Leu Met Gln
1685 1690 1695
Leu Gln Glu Asp Leu Ala Ala Ala Glu Arg Ala Arg Lys Gln Ala
1700 1705 1710
Asp Leu Glu Lys Glu Glu Leu Ala Glu Glu Leu Ala Ser Ser Leu
1715 1720 1725
Ser Gly Arg Asn Ala Leu Gln Asp Glu Lys Arg Arg Leu Glu Ala
1730 1735 1740
Arg Ile Ala Gln Leu Glu Glu Glu Leu Glu Glu Glu Gln Gly Asn
1745 1750 1755
Met Glu Ala Met Ser Asp Arg Val Arg Lys Ala Thr Gln Gln Ala
1760 1765 1770
Glu Gln Leu Ser Asn Glu Leu Ala Thr Glu Arg Ser Thr Ala Gln
1775 1780 1785
Lys Asn Glu Ser Ala Arg Gln Gln Leu Glu Arg Gln Asn Lys Glu
1790 1795 1800
Leu Arg Ser Lys Leu His Glu Met Glu Gly Ala Val Lys Ser Lys
1805 1810 1815
Phe Lys Ser Thr Ile Ala Ala Leu Glu Ala Lys Ile Ala Gln Leu
1820 1825 1830
Glu Glu Gln Val Glu Gln Glu Ala Arg Glu Lys Gln Ala Ala Thr
1835 1840 1845
Lys Ser Leu Lys Gln Lys Asp Lys Lys Leu Lys Glu Ile Leu Leu
1850 1855 1860
Gln Val Glu Asp Glu Arg Lys Met Ala Glu Gln Tyr Lys Glu Gln
1865 1870 1875
Ala Glu Lys Gly Asn Ala Arg Val Lys Gln Leu Lys Arg Gln Leu
1880 1885 1890
Glu Glu Ala Glu Glu Glu Ser Gln Arg Ile Asn Ala Asn Arg Arg
1895 1900 1905
Lys Leu Gln Arg Glu Leu Asp Glu Ala Thr Glu Ser Asn Glu Ala
1910 1915 1920
Met Gly Arg Glu Val Asn Ala Leu Lys Ser Lys Leu Arg Gly Pro
1925 1930 1935
Pro Pro Gln Glu Thr Ser Gln
1940 1945
Claims (8)
1. Use of a kit for detecting the presence of a MYH11 protein for the preparation of a medicament for the diagnosis and/or prevention and/or treatment of chronic coronary heart disease, for in vitro diagnosis and/or risk stratification of chronic coronary heart disease, for the determination of a body fluid sample selected from serum.
2. Use according to claim 1, characterized in that: the kit is used for determining the expression amount of MYH11 protein in a body fluid sample.
3. Use according to claim 2, characterized in that: the expression level of MYH11 protein in the body fluid sample is positively correlated with the severity of chronic coronary heart disease.
4. Use according to claim 2, characterized in that: the kit detects the expression quantity of MYH11 protein by an ELISA method.
5. Use according to claim 1, characterized in that: the medicament is used for diagnosing or monitoring the existence and/or the process and/or the severity and/or the prognosis of chronic coronary heart disease.
Application of MYH11 protein or peptide fragment thereof as biomarker in preparation or screening of chronic coronary heart disease diagnostic reagent for determination of body fluid sample selected from serum.
7. Use according to claim 6, characterized in that: MYH11 protein level of patients with chronic coronary heart disease is high-expressed.
8. Use according to claim 6, characterized in that: MYH11 protein in serum of patients with chronic coronary heart disease is more than or equal to 1990.0218 pg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910251994.7A CN110082535B (en) | 2019-03-29 | 2019-03-29 | Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910251994.7A CN110082535B (en) | 2019-03-29 | 2019-03-29 | Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110082535A CN110082535A (en) | 2019-08-02 |
| CN110082535B true CN110082535B (en) | 2022-06-10 |
Family
ID=67413948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910251994.7A Active CN110082535B (en) | 2019-03-29 | 2019-03-29 | Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110082535B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107653309A (en) * | 2017-08-30 | 2018-02-02 | 广东省心血管病研究所 | Applications of the MIR135HG in cardiovascular system is regulated and controled |
| CN108700597A (en) * | 2016-02-16 | 2018-10-23 | 公立大学法人横浜市立大学 | Biomarker in blood for detecting artery sclerosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120316211A1 (en) * | 2011-05-11 | 2012-12-13 | The Board or Regents of the University of Texas System | Diagnostic Methods for Assessing Risk of Chagas Disease and Heart Failure |
| CN107022605B (en) * | 2017-02-27 | 2019-10-15 | 广东医科大学 | A kind of biomarker of active tuberculosis |
-
2019
- 2019-03-29 CN CN201910251994.7A patent/CN110082535B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108700597A (en) * | 2016-02-16 | 2018-10-23 | 公立大学法人横浜市立大学 | Biomarker in blood for detecting artery sclerosis |
| CN107653309A (en) * | 2017-08-30 | 2018-02-02 | 广东省心血管病研究所 | Applications of the MIR135HG in cardiovascular system is regulated and controled |
Non-Patent Citations (4)
| Title |
|---|
| CORONARY ARTERY COMPLICATIONS FOLLOWING AORTIC ROOT REPLACEMENT IN FAMILIAL AORTIC ANEURYSMS ARE COMMON AND SUPPORT NEED FOR LONG-TERM SURVEILLANCE;Krishna Hema 等;《JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY》;20160402;第67卷(第13期);第968-968页 * |
| 冠心病血瘀证差异蛋白质生物信息学分析;孟莉娟等;《中医药导报》;20170715(第13期);全文 * |
| 无标记定量法研究冠心病不稳定性心绞痛血瘀证的差异蛋白质组;赵慧辉等;《高等学校化学学报》;20100210(第02期);全文 * |
| 血管平滑肌细胞与动脉粥样硬化关系的研究进展;袁帅等;《实用心脑肺血管病杂志》;20180225(第02期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110082535A (en) | 2019-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ueshima et al. | Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population | |
| Jin et al. | Risk factors for worsening of acute pancreatitis in patients admitted with mild acute pancreatitis | |
| US20100105046A1 (en) | Methods of diagnosing cardiovascular disease | |
| Zaharieva et al. | Prevalence of positive diabetes-associated autoantibodies among type 2 diabetes and related metabolic and inflammatory differences in a sample of the Bulgarian population | |
| CN110426523B (en) | Use of AIM as biomarker for diagnosis, prognosis and therapy monitoring of rheumatoid arthritis | |
| Al-Refai et al. | Urinary neutrophil gelatinase associated lipocalin as a marker of tubular damage in type 2 diabetic patients with and without albuminuria | |
| Zhao et al. | The relationship between benign prostatic hyperplasia/lower urinary tract symptoms and mean platelet volume: the role of metabolic syndrome | |
| Petrov et al. | Metabolic sequelae: the pancreatitis zeitgeist of the 21st century | |
| Selcuk et al. | The relation between differential leukocyte count, neutrophil to lymphocyte ratio and the presence and severity of coronary artery disease | |
| CN110082535B (en) | Molecular marker MYH11 for diagnosing chronic coronary heart disease and application thereof | |
| WO2019097089A1 (en) | Methods for prediction and early detection of diabetes | |
| Lacombe et al. | Factors associated with circulating zonulin in inflammatory bowel disease | |
| Silaghi et al. | Circulating matrix Gla protein: a potential tool to identify minor carotid stenosis with calcification in a risk population | |
| CN110824171B (en) | Application of a group of metabolic markers in early diagnosis of coronary heart disease events of patients with metabolic syndrome | |
| Wang et al. | Growth differentiation factor-15 is a prognostic marker in patients with intermediate coronary artery disease | |
| KR100981831B1 (en) | Method for evaluating insulin resistance | |
| RU2630592C1 (en) | Method for predicting development of postpericardiotomy syndrome in patients with ihd after coronary artery bypass surgery | |
| Balci et al. | T786C and G894T eNOS Polymorphısms as a Risk Assessment of Coronary Artery Dısease | |
| Erman et al. | Beta cell function as an assessment tool for cardiovascular risk in patients with metabolic syndrome | |
| AbdelAal et al. | Study of subclinical atherosclerosis in patients with type 2 diabetes mellitus | |
| Jun et al. | Uric acid is associated with cardiac death in patients with hypertrophic obstructive cardiomyopathy | |
| Mohammed | Mutations in the Interleukin-15 Gene as a Molecular Biomarker in the Atherosclerosis Disease. | |
| EL-SAYED et al. | Circulating adipocyte fatty acid binding protein (A-FABP): Predictor of metabolic syndrome in patients with type 2DM | |
| Kong et al. | Reference intervals for circulating angiogenic cytokines | |
| Kurt et al. | Investigation of the Relationship Between Left Ventricular Hypertrophy and Endothelial Dysfunction in Patients with Primary Hypertension by ADMA and hsCRP |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |